Klebsiella pneumoniae
Vaccines - Commercial Forecast
The WHO's #1 critical-priority pathogen. A major cause of neonatal sepsis in the developing world. No licensed vaccine exists. This is the most comprehensive independent commercial assessment of the Kp vaccine opportunity -118 nations, scenario-based forecasting, fully updated for the Eli Lilly/LimmaTech acquisition.
- Format
- PDF + Excel model
- Presentation slides
- >225 slides
- Excel worksheets
- 120 sheets
- Nations modelled
- 118
- Markets
- Public & private
- Approach
- Scenario-based
Pathogen 2024
annually (GBD 2023)
incl. GAVI countries
acquisition, May 2026
Why Klebsiella pneumoniae demands a vaccine solution
Understanding the pathogen is central to understanding the commercial opportunity. The burden is substantial across both high-income hospital settings and low-income neonatal populations - two very different markets with very different vaccine profiles.
Pathogen overview - Klebsiella pneumoniae (Kp)
Klebsiella pneumoniae is an encapsulated, Gram-negative non-motile bacterium of the enterobacterales family which typically colonises the oropharynx and gastrointestinal tract. The classical form is mainly an opportunistic nosocomial/ICU pathogen causing disease in immunocompromised or at-risk individuals with comorbidities. Common Kp-related infections include pneumonia, urinary tract infection (UTI), intraabdominal infection, bloodstream infection (BSI) and meningitis. A hypervirulent form (hvKp) is additionally capable of causing community-acquired infections - often in healthy individuals - with significant morbidity and mortality.
In the developing world, Kp is the most common pathogen isolated in neonatal sepsis cases globally, responsible for approximately 75,000 pneumonia deaths in children under five and 34,000 neonatal deaths alone in 2023 (GBD 2023). Worldwide across all syndromes, Kp caused an estimated 228,000 lower respiratory infection deaths in 2023, ranking it as the 3rd leading bacterial cause of LRI deaths globally. The CHAMPS surveillance network has additionally documented 84% ceftriaxone resistance in Kp neonatal sepsis isolates, highlighting the severity of the antimicrobial resistance (AMR) problem in this patient group.
Kp exhibits a high degree of antimicrobial resistance. Carbapenem-resistant K. pneumoniae (CRKP) was ranked the #1 critical-priority pathogen in the updated WHO Bacterial Priority Pathogens List 2024 - scoring 84%, the highest of all 24 pathogens evaluated. ESBL-producing and carbapenem-resistant (CRE) strains are both considered critical threats. The convergence of hypervirulence and carbapenem resistance in emergent hvKp strains represents a particularly concerning trajectory.
The race for a Kp vaccine - where things stand
No licensed Klebsiella pneumoniae vaccine currently exists. The most advanced candidate (Kleb4V) completed Phase 1/2 before GSK's pipeline exit - and has since become the subject of the most significant bacterial vaccine acquisition in years.
-
LimmaTech / GSKNow: Eli LillyKleb4V (GSK4429016A) Phase 1/2 completeGSK pipeline exit Q1 2024
Tetravalent O-antigen bioconjugate with AS03 adjuvant. Phase 1/2 (NCT04959344) results published in J. Infect. Dis. (2026): immunogenic and well tolerated in adults 55-70 yrs, with IgG responses to all four serotypes persisting to 6 months. Status under Lilly ownership currently to be clarified. -
Vaxdyn (Spain)Phase 1AK-VAX Phase 1A
Whole-cell outer membrane antigen vaccine advancing toward Phase 1A trials. Supported by CARB-X and the European Innovation Council (EIC). One of the most advanced non-GSK Kp candidates. In September 2026, Vaxdyn closed an €11m Series A round (Biovance Capital, Arcano Partners' Impacto Andalucía fund, EIC Fund) specifically to fund K-VAX's first-in-human Phase 1 trial. -
SyntironPreclinicalAlloy-EK (maternal vaccine)
CARB-X award of US$1.7 million (January 2024). Targets both E. coli and Kp to prevent neonatal sepsis via maternal immunisation. Addresses the most acute developing-world mortality burden directly. -
InventprisePreclinicalConjugate Klebsiella vaccine
Focused on reducing neonatal mortality in low-income settings. Conjugate approach targeting key serotypes. -
OmniosePreclinicalMultivalent bioconjugate
Targeting both capsular and O-antigen polysaccharides. Broad-spectrum approach with NIH grant backing. Aims to address the serotype coverage challenge. -
GSK / AffinivaxEarly stageEarly-stage Kp candidate
GSK pipeline includes an early-stage Kp programme via its Affinivax acquisition. Development stage remains early. As of WHO PDVAC 2024, no candidate had reached clinical development beyond the now-discontinued Kleb4V.
Eli Lilly acquired LimmaTech Biologics in May 2026 for up to $780 million - signalling renewed major pharma commitment to bacterial vaccine development. Lilly's near-term focus is LimmaTech's lead S. aureus vaccine (LBT-SA7, Phase 1) and preclinical gonorrhoea/chlamydia programmes. The status of Kleb4V under Lilly's ownership therefore remains to be clarified - and represents a significant strategic watch point for the Kp vaccine landscape. The VacZine Analytics model assesses multiple pipeline scenarios accordingly.
Six analytical layers - one commercial picture
The MarketVIEW Kp analysis provides a rigorous commercial assessment that spans disease burden, target population rationale, vaccine profiles, scenario-based revenue forecasting and pipeline tracking across 118 nations.
Public and private market forecasts across high-income and GAVI/developing world countries. Separate scenario outputs for hospital-acquired, neonatal and community-acquired indications.
In-depth rationale for each target group: ICU/surgical patients, haemodialysis/ESRD patients, neonates (maternal immunisation), GAVI-eligible populations. Population sizing and uptake modelling included.
Comprehensive review of all active and discontinued Kp vaccine programmes - antigen strategies, adjuvant systems, serotype coverage and development feasibility. Kleb4V Phase 1/2 data assessed in full.
Multiple commercial scenarios modelled - base, upside and conservative - with assumptions around clinical success probability, pricing, reimbursement and public health programme inclusion for each target group.
Updated epidemiology using GBD 2023 data, WHO BPPL 2024 resistance classifications and CHAMPS neonatal surveillance. LRI deaths, neonatal deaths, CRKP burden and hypervirulent Kp trends all covered.
Vaccine profile commercial feasibility discussion covering pricing rationale, public procurement dynamics (GAVI, PAHO), private payer landscape in HI countries, and clinical development cost-benefit considerations.
A glimpse of the commercial model
The table below shows a partial view of the target population and scenario framework. Full revenue outputs, pricing assumptions and country-level data are in the licensed model.
| Target population | Geography | Market type | Vaccine profile | Revenue scenario |
|---|---|---|---|---|
| ICU / surgical patients | HI countries | Private / hospital | Prophylactic (pre-admission) | Modelled |
| Haemodialysis / ESRD | USA + EU5 | Public programme | Annual / booster | Modelled |
| Neonates (maternal route) | GAVI nations | Public / donor | Maternal immunisation | Modelled |
| ███████████████ | ████████ | ██████ | ████████████ | $██m (base) |
| ███████████████ | ████████ | ██████ | ████████████ | $██m (upside) |
| Total addressable - base | 118 nations | All | All profiles | $███m |
What you receive
A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model - designed for decision-makers who need the full picture on the Kp vaccine opportunity.
- Executive presentation (>225 slides, PDF) - disease background, epidemiology, resistance trends, pipeline analysis and commercial assessment with full supporting narrative and references
- Interactive MS-Excel forecast model (120 worksheets) - 118-nation volume and revenue outputs, scenario toggles, target population breakdowns and pricing assumptions across public and private markets
- Scenario-based commercial forecasts - base, upside and conservative scenarios for each target population, with explicit assumptions on clinical success probability and market access
- Pipeline intelligence - Kleb4V Phase 1/2 data assessed, Eli Lilly/LimmaTech acquisition implications analysed, all active preclinical programmes reviewed including Vaxdyn, Syntiron, Inventprise and Omniose
- Updated epidemiology module - GBD 2023 burden data, WHO BPPL 2024 rankings, neonatal sepsis surveillance (CHAMPS) and CRKP/ESBL resistance trends
- GAVI / developing world analysis - separate modelling for low-income country public health programmes including maternal immunisation scenarios and PAHO pricing dynamics
Built for organisations assessing the bacterial vaccine opportunity
This report is most valuable to teams evaluating the Kp landscape against their own pipeline, BD ambitions or investment thesis - particularly in the context of the Lilly/LimmaTech transaction and WHO AMR prioritisation.
Vaccine developers
Pipeline positioning, commercial feasibility and target population prioritisation for Kp vaccine candidates at any stage.
Corporate strategy & BD
Validate the Kp commercial opportunity size and structure against internal thresholds. Understand the competitive landscape post-Lilly acquisition.
Investors & analysts
Independent assessment of the Kp vaccine market size and pipeline risk profile for due diligence on bacterial vaccine assets.
Global health funders
GAVI, CEPI, CARB-X and bilateral funders assessing the case for Kp vaccine investment in low-income neonatal settings.
AMR researchers & academia
Comprehensive epidemiology, resistance data and vaccine pipeline landscape for grant proposals and translational research planning.
Market access & policy
Pricing benchmarks, procurement dynamics and public health programme feasibility analysis across 118 nations.
VacZine Analytics has tracked the Klebsiella pneumoniae vaccine pipeline since its earliest commercial assessments. This analysis is unique in combining a rigorous epidemiological and clinical review with an independently constructed 118-nation commercial model - covering both the high-income hospital market and the GAVI-eligible neonatal mortality context that most commercial forecasts ignore entirely.
The model has been updated to reflect the Eli Lilly acquisition of LimmaTech Biologics (May 2026), Phase 1/2 immunogenicity data for Kleb4V (J. Infect. Dis., 2026) and the WHO Bacterial Priority Pathogens List 2024. It remains one of the most frequently accessed reports in the VacZine Analytics portfolio.
License the Kp vaccine commercial model
Contact VacZine Analytics for pricing, sample slides and licensing terms. Single-licence and multi-user options available. Briefing call included on request.